Medicaid Bulletin

SPECIAL BULLETIN COVID #128: NC Medicaid Optional COVID-19 Testing Program Online Applications Available

Wednesday, September 2, 2020

NC Medicaid is reimbursing COVID-19 testing costs for individuals without insurance who enroll in the NC Medicaid Optional COVID-19 Testing (MCV) program. 

SPECIAL BULLETIN COVID-19 #127: Antigen Testing Guidance

Tuesday, September 1, 2020

Providers are required by State Health Director Order to report all results, positive and negative, of diagnostic testing for SARS-CoV-2, the virus that causes COVID-19.

Influenza Vaccine and Reimbursement Guidelines for 2020-2021 for Medicaid and NC Health Choice

Tuesday, September 1, 2020

NC Immunization Program/Vaccines for Children (NCIP/VFC), Billing/Reporting Influenza Vaccines for Medicaid Beneficiaries, Borrowing and Replacement of VFC and Private Vaccines, Borrowing and Replacement of VFC and Private Vaccines, Billing/Reporting Influenza Vaccines for NC Health Choice Beneficiaries, Immunization Billing for Medicaid and NC Health Choice Beneficiaries from FQHCs and RHCs and NDC’s Change Each Year for Influenza Vaccines.  

SPECIAL BULLETIN COVID-19 #126: New Deadline for Medicaid Providers Applying for Federal Relief Funds

Friday, August 28, 2020

The deadline for Medicaid/CHIP providers to submit their financial data to apply for federal provider relief funds has been extended to Sept. 13, 2020. 

SPECIAL BULLETIN COVID-19 #125: Webinar on Updated CDC Dental Guidance

Thursday, August 27, 2020

NC DHHS and the NC Area Health Education Center (AHEC) are partnering in a free webinar series offering guidance to dental professionals.

Pertuzumab, Trastuzumab and Hyaluronidase-zzxf Injection, for Subcutaneous use (Phesgo™) HCPCS Code J9999: Billing Guidelines

Tuesday, August 25, 2020

Effective with date of service July 1, 2020, the Medicaid and NC Health Choice programs cover pertuzumab, trastuzumab, and hyaluronidase-zzxf injection, for subcutaneous use (Phesgo™) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code J9999 - Not otherwise classified, antineoplastic drugs.

Mitomycin for Pyelocalyceal Solution (Jelmyto™) HCPCS Code J9999: Billing Guidelines

Tuesday, August 25, 2020

Effective with date of service June 17, 2020, the Medicaid and NC Health Choice programs cover mitomycin for pyelocalyceal solution (Jelmyto™) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code J9999 - Not otherwise classified, antineoplastic drugs.

Lurbinectedin for Injection, for Intravenous Use (Zepzelca™) HCPCS Code J9999: Billing Guidelines

Tuesday, August 25, 2020

Effective with date of service June 19, 2020, the Medicaid and NC Health Choice programs cover lurbinectedin for injection, for intravenous use (Zepzelca™) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code J9999 - Not otherwise classified, antineoplastic drugs.

Bimatoprost Implant, for Intracameral Administration (Durysta™) HCPCS Code J3490: Billing Guidelines

Tuesday, August 25, 2020

Effective with date of service June 26, 2020, the Medicaid and NC Health Choice programs cover bimatoprost implant, for intracameral administration (Durysta™) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code J3490 - Unclassified drugs.

Behavioral Health I/DD Tailored Plan Memo on State-Funded Services Design Updates

Thursday, August 20, 2020

A memo regarding North Carolina’s Design for State-Funded Services Under Behavioral Health and Intellectual/Developmental Disability Tailored Plans white paper has been released.

Subscribe to Medicaid Bulletins Updates

Medicaid Bulletin Monthly Digest

Medicaid Bulletin Archive

Articles beginning January 2018 are available in the blog format.

Associated Files